NCT01057160已完成4 期
A Study of the Efficacy and Safety of Rizatriptan 10 mg RPD in the Treatment of Acute Migraine in Patients With Non Satisfactory Response to Previous Pharmacologic Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 195
- 试验地点
- 1
- 主要终点
- Percentage of patients with headache response on a one to four scale after 2 hours.
研究概览
简要总结
This is a multicentre, open label, prospective, randomized, two-attack study with active comparator in patients reporting inadequate response to analgesics and/or triptans to examine the efficacy of Rizatriptan 10 mg RPD in this group of patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient's signature on the informed consent document [each patient should be given ample time to read (or have read to them) the consent form, ask any questions they may have regarding the trial and have a clear understanding of the trial and the procedures involved prior to the signing of the consent form].
- •Have a clinical diagnosis of migraine with or without aura according to IHS criteria at least one year prior to enrollment.
- •At screening at least two migraine attacks per month and no more than ten during the last three months prior to inclusion.
- •At screening a stable dose of prophylactic medication (including no prophylactic treatment) for at least two months and no change of prophylactic medication during active trial period.
排除标准
- •Contraindication to triptans or Rizatriptan according to medical information sheet.
- •Patient has a history or clinical evidence of ischemic heart disease (e.g., angina pectoris of any type, history of myocardial infarction or documented silent ischemia) or symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm (including Prinzmetal's variant angina), or other significant underlying cardiovascular disease. Patient has uncontrolled hypertension. Patient has either demonstrated hypersensitivity to or experienced a serious adverse event in response to Rizatriptan or any of its inactive ingredients.
- •History of treatment failure for at least one triptan for the treatment of acute migraine attacks.
- •Any other headache, except tension type headache on 5 or less days a month within three months prior to screening.
- •A history of drug induced headache, medication overuse headache or any other addiction.
- •Any history of allergic hypersensitivity or poor tolerance to any components of the preparations used in this trial.
- •Females of childbearing potential not using reliable means of birth control, pregnant or lactating females or expected/ planned pregnancy.
- •Participation (planned or current) in any investigational drug or device trial within the previous 30 days prior to screening visit.
- •Inability to understand the trial procedures, and thus inability to give informed consent.
- •History of allergy to sulfa drugs.
研究组 & 干预措施
intake of rizatriptan 10 mg
Experimental
干预措施: Rizatriptan (Drug)
previous used analgesic
Active Comparator
干预措施: Rizatriptan (Drug)
结局指标
主要结局
Percentage of patients with headache response on a one to four scale after 2 hours.
时间窗: 2 hours
次要结局
- Percentage of patients being headache free two hours after intake of study medication. Time of dosing to onset of headache relieve. Relief of concomitant symptoms. Rate of sustained pain free Percentage of patients needing rescue medication((time points 0.5, 1, 1.5, 2, 4, 8, 12, 24 hours after drug intake)
研究者
Hans-Christoph Diener
Prof. of Neurology
Universität Duisburg-Essen
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)Migraine, AcuteNCT01001234Organon and Co1,382
已完成
3 期
A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine ProphylaxisMigraineNCT00812006Organon and Co108
已完成
3 期
Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)MigraineNCT00516737Organon and Co207
撤回
不适用
Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military TroopsChronic Post-traumatic HeadacheNCT01306266Henry M. Jackson Foundation for the Advancement of Military Medicine
已完成
3 期
Treatment of Multiple Attacks of Acute Migraine (0462-025)Migraine HeadacheNCT00899379Organon and Co473